Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension

Through a randomized controlled trial (RCT) design, this study aiming to evaluated the efficacy and safety of rituximab lymph node injection combined with pulmonary vascular interventional therapy in treating fibrosing mediastinal pulmonary hypertension (FM-PH).Eligible participants were randomly assigned to either the combined treatment group, receiving both pulmonary vascular intervention and rituximab lymph node injection, or the interventional-only group, which received pulmonary vascular intervention alone. At 3, 6, and 12 months post-treatment, the efficacy was assessed based on symptom improvement, hemodynamic changes, lesion volume reduction, etc. Safety was mainly evaluated by comparing adverse event incidence between the two groups.

NCT Number	NCT06980584
Lead Sponsor	Beijing Chao Yang Hospital Collaborators: Beijing Municipal Health Commission
Conditions	Fibrosing Mediastinitis, Pulmonary Hypertension
Enrollment	48 participants
Start Date	2025-02-10
Primary Completion	2027-10-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-23